Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-07-25

Clinical Trial Update: A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis [Phase 2]

View source ↗

Summary

Phase II placebo-controlled trial evaluating 28 days of oral AZD9668 in bronchiectasis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AZD9668 (AZD9668)

Snippet

Sponsor: AstraZeneca | Conditions: Bronchiectasis | Phase 2 | Status: COMPLETED | Results posted: 2012-07-25